Alzamend Neuro, Inc.

NASDAQ (USD): Alzamend Neuro, Inc. (ALZN)

Last Price

2.029

Today's Change

-0.08 (3.79%)

Day's Change

1.96 - 2.08

Trading Volume

246,572

Overview

Market Cap

1 Million

Shares Outstanding

841,240

Avg Volume

1,641,146

Avg Price (50 Days)

3.23

Avg Price (200 Days)

7.02

PE Ratio

-0.01

EPS

-147.00

Earnings Announcement

12-Sep-2024

Previous Close

2.11

Open

2.06

Day's Range

1.96 - 2.08

Year Range

1.835 - 40.05

Trading Volume

246,572

Price Change Highlight

1 Day Change

-3.79%

5 Day Change

-6.88%

1 Month Change

-7.73%

3 Month Change

-58.57%

6 Month Change

-81.88%

Ytd Change

-77.93%

1 Year Change

-94.14%

3 Year Change

-99.51%

5 Year Change

-99.90%

10 Year Change

-99.90%

Max Change

-99.90%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment